Stockreport

FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients

Athersys, Inc.  (ATHX) 
Last athersys, inc. earnings: 11/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: athersys.com/press-releases
PDF Phase 2 study of cell therapy in trauma expands Company’s clinical programs focused on critical care CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announ [Read more]